LS Investment Advisors LLC boosted its position in shares of Stryker Corporation (NYSE:SYK) by 3.6% during the 4th quarter, Holdings Channel reports. The firm owned 10,249 shares of the medical technology company’s stock after acquiring an additional 354 shares during the quarter. LS Investment Advisors LLC’s holdings in Stryker were worth $1,587,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of SYK. Sawyer & Company Inc bought a new position in Stryker during the 4th quarter valued at about $125,000. Sit Investment Associates Inc. grew its stake in Stryker by 114.3% in the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after acquiring an additional 440 shares in the last quarter. San Francisco Sentry Investment Group CA grew its stake in Stryker by 47.8% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 325 shares in the last quarter. Oak Point Wealth Management bought a new position in Stryker in the 4th quarter worth about $145,000. Finally, Dubuque Bank & Trust Co. bought a new position in Stryker in the 4th quarter worth about $164,000. Institutional investors own 74.71% of the company’s stock.

Stryker Corporation (NYSE:SYK) opened at $153.66 on Tuesday. The stock has a market cap of $56,653.36, a price-to-earnings ratio of 23.30, a price-to-earnings-growth ratio of 2.17 and a beta of 0.70. Stryker Corporation has a fifty-two week low of $123.34 and a fifty-two week high of $170.00. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The firm’s revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the business earned $1.78 earnings per share. sell-side analysts expect that Stryker Corporation will post 7.12 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.22%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s dividend payout ratio is currently 70.15%.

In other news, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $160.53, for a total transaction of $479,021.52. Following the completion of the transaction, the insider now directly owns 9,100 shares in the company, valued at $1,460,823. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,840 shares of company stock worth $2,749,989. Insiders own 7.40% of the company’s stock.

SYK has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Stryker from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Robert W. Baird restated a “hold” rating and issued a $161.00 target price on shares of Stryker in a research note on Friday, October 27th. Piper Jaffray Companies restated a “buy” rating and issued a $156.00 target price on shares of Stryker in a research note on Friday, October 27th. Wells Fargo & Co upped their target price on shares of Stryker from $160.00 to $166.00 in a research note on Friday, October 27th. Finally, Stifel Nicolaus upped their target price on shares of Stryker from $158.00 to $168.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Stryker presently has an average rating of “Hold” and a consensus target price of $162.50.

TRADEMARK VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://theolympiareport.com/2018/02/13/ls-investment-advisors-llc-has-1-59-million-position-in-stryker-corporation-syk.html.

Stryker Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.